SCR 6852
Alternative Names: SCR-6852; SIM-0270Latest Information Update: 07 Aug 2024
At a glance
- Originator Jiangsu Simcere Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer
- Preclinical Brain metastases
Most Recent Events
- 23 Jul 2024 Simcere Pharmaceutical initiates phase-I pharmacokinetics trial (In Volunteers) in China (PO) (NCT06536036)
- 05 Dec 2023 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 18 May 2022 Phase-I clinical trials in Breast cancer (Late-stage disease, Combination therapy, Metastatic disease) in China (PO) (NCT05293964)